• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A biotech company developing and commercializing vaccines for infectious diseases with major unmet needs


Download 2017 Valneva Annual Business Report

January 16, 2019
Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

Read more

— Stock information


— January 16, 2019
Valneva Announces New $59 Million IXIARO® Supply Contract with US Government

Read more
— Vienna Stock Exchange Delisting /
Delisting von der Wiener Börse

Shareholder information
Informationen für Aktionäre

— Financial Calendar
February 21, 2019
Revenues 2018

March 21, 2019
2018 Financial Statements

See all dates


News in German


Images, presentations and videos


learn more
play video Company Video

– Upcoming conferences

January 31, 2019
Degroof Petercam's Healthcare Seminar, Brussels

April 15-17, 2019
World Vaccine Congress, Washington D.C.
Please update your browser...